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Abstract Formation of PrP aggregates is considered to
be a characteristic event in the pathogenesis of TSE dis-
eases, accompanied by brain inXammation and neurode-
generation. Factors identiWed as contributing to aggregate
formation are of interest as potential therapeutic targets.
We report that in vitro proteolysis of ovine PrP94–233 (at
neutral pH and in the absence of denaturants) by the
protease cathepsin S, a cellular enzyme that also shows
enhanced expression in pathogenic conditions, occurs
selectively in the region 135–156. This results in an
unusually eYcient, concentration-dependent conforma-
tional conversion of a large subfragment of PrP94–233 into
a soluble -structured oligomeric intermediate species,
that readily forms a thioXavin-T-positive aggregate. N-
terminal sequencing of the proteolysis fragments shows
the aggregating species have marked sequence similarities
to truncated PrP variants known to confer unusually
severe pathogenicity when transgenically expressed in
PrPo/o mice. Circular dichroism analysis shows that PrP
fragments 138–233, 144–233 and 156–233 are signiW-
cantly less stable than PrP94–233. This implies an important
structural contribution of the 1 sequence within the glob-
ular domain of PrP. We propose that the removal or
detachment of the 1 sequence enhances -oligomer for-
mation from the globular domain, leading to aggregation.
The cellular implications are that speciWc proteases may
have an important role in the generation of membrane-
bound, potentially toxic, -oligomeric PrP species in pre-
amyloid states of prion diseases. Such species may induce
cell death by lysis, and also contribute to the transport of
PrP to neuronal targets with subsequent ampliWcation of
pathogenic eVects.
Keywords Proteolysis · Circular dichroism · 
ThioXavin-T · Truncation mutants · Pathogenicity
Abbreviations
PrP Prion protein
PrP94–233 The globular domain of PrP
PrPc Cellular PrP
PrPSc The scrapie form of PrP
PrP Proteolytic fragments are identiWed by their
N-terminal sequences, eg 135SAMS
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The prion protein (PrP) is a key molecule in transmissible
spongiform encephalopathies or prion diseases, (reviewed in
Prusiner 1998). However, the precise mechanism of the trans-
formation in vivo of the normal -helical containing cellular
form (PrPc) to a highly associated -structured form, identiWed
by FTIR (Pan et al. 1993), and typiWed in many diseased states
by characteristic deposits, such as the toxic scrapie form, PrPSc,
is still unknown (Caughey and Baron 2006). Extensive bio-
physical work has demonstrated the conformational conversion
of recombinant PrP from - to -forms under a variety of in
vitro solution conditions that include low pH, denaturants, salts
and detergents, often with prolonged mechanical agitation.
These treatments result in the formation of -oligomers and in
some cases, amyloid Wbril structures. (e.g: Swietnicki et al.
2000; Morillas et al. 2001; Baskakov et al. 2001; Baskakov
et al. 2002; Rezaei et al. 2005). Aggregated Wbrillar forms of
recombinant PrP (‘synthetic prions’ Legname et al. 2004))
have been shown to cause disease in animal models; however,
the demonstration of the toxicity of oligomeric forms of PrP
derived from PrPSc (Silveira et al. 2005) indicates that certain
non-amyloidal forms are also potentially toxic.
Many prion diseases associated with natural and trans-
genically expressed PrP mutants involve a very slow devel-
opment (Prusiner 1998). By contrast, it has been shown that
the expression in transgenic PrPo/o mice of PrPc containing
deletions of amino acids 32–134, 94–134 or 105–125 cre-
ates unexpectedly severe neuropathological phenotypes.
These include ataxial behaviour and myelin vacuolar
degeneration of the brain, occurring without detectable
deposition of the typical protease-resistant PrPSc deposits
characteristic of the scrapie condition, (Shmerling et al.
1998; Baumann et al. 2007; Li et al. 2007). The molecular
basis of this neuropathology, and its suppression by co-
expression of normal PrPc, is also unknown.
These results indicate a potential role for proteolysed forms
of PrP in certain prion disease mechanisms. Intra- and extra-
cellular proteases have been shown to be of potential impor-
tance in the modiWcation of neuronal receptors (Saito and
Bunnett 2005) and development of prion diseases(Parkin et al.
2007; Yadavalli et al. 2004), and abnormal traYcking, folding
and targeting of the cellular protein have been implicated in
prion pathogenesis (Tatzelt and Schatzl 2007).
In this work we examine the conformational consequences
of proteolysis of PrP by members of a ubiquitous family of
proteases, the cathepsins, which exhibit wide-ranging cellular
functions [Turk et al. 2000]. Cathepsin S is a cysteine protease
that is able to work outside the lysosome and in a wide range
of pH; it is secreted by microglia and over-expressed in scrapie
brain (Baker et al. 1999; Xiang et al. 2004). We examine the
eVects of in vitro proteolysis of PrP by cathepsin S, and show
that it causes speciWc and limited N-terminal truncation of
PrP94–233. This induces an unusually eYcient, protein concen-
tration dependent,  !  conformational conversion, initially
forming a soluble -structured intermediate species, that leads
to thioXavin T-positive PrP aggregated species. Sequence anal-
ysis of the proteolytic fragments shows a striking similarity
between these truncated species and the PrP variants of known
high toxicity in PrPo/o transgenic mice, (Shmerling et al. 1998;
Baumann et al. 2007; Li et al. 2007). Recombinant expression
of the proteolytic fragments shows that the absence of
sequences including the 1 residues results in decreased stabil-
ity and solubility of the PrP globular domain. This suggests
proteases may act as a general trigger mechanism for the for-
mation of -structured oligomeric forms under physiological
conditions, and indicates a potential role of proteolytic pro-
cesses in contributing to rapid toxicity and to longer-term prion
pathogenesis.
Experimental
Protein expression and puriWcation
The hexa-His tagged ovine PrP94–233 (ARQ allele) was
expressed and puriWed as described (Haire et al. 2004) with
small modiWcations. The cell lysate was centrifuged at
20,000g for 20 min. The resulting pellet was dissolved in
buVer A (10 ml per 1 g of pellet; 100 mM Tris (pH 8.0), 8 M
Urea), incubated for 2 h at room temperature, and centri-
fuged at 20,000g for 15 min to remove insoluble material.
The solubilized inclusion bodies were incubated with Ni-
NTA Agarose (Qiagen) at 4°C for 1 h on a rocker table. The
NTA column was washed to remove unbound protein with
Wve volumes of buVer A. Refolding of PrP was achieved
with PrP still bound to the resin by resuspending the pelleted
resin in cold refolding buVer (50 mM Tris, pH7.5). This mix-
ture was incubated for 30 min at 4°C with rocking. PrP was
eluted from the resin in refolding buVer supplemented with
500 mM imidazole pH 7.5, and dialyzed against 50 mM
sodium acetate (pH 5.5). The purity of the Wnal rPrP prepara-
tion was conWrmed by SDS-PAGE, and far UVCD spectros-
copy was used to conWrm the correctly folded structure.
Protein concentration was determined on the Jasco V550
spectrophotometer, with a calculated 280 for OvPrP94–233 of
23,505 M¡1 cm¡1. OvPrP138¡233, PrP144–233 and PrP156–233,
were similarly expressed, but with a protease-sensitive His
tag that is removed either in the NTA-attached state, or fol-
lowing the imidazole elution step. Prolonged storage of PrP
in Tris buVer was avoided, since it causes degradation.
Circular dichroism spectroscopy and analysis
CD experiments were performed at 30°C in 50 mM MES at
pH 5.5–6.5 with protein concentrations 6–60 M in a 1 or123
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from 260 to (maximally) 190 nm on a Jasco J-715 spectro-
polarimeter at 20 nm/min with bandwidth 2.0 nm. 25 CD
scans were averaged, smoothed by instrumental software
and the data expressed as CD extinction coeYcient, mrw
(M¡1 cm¡1)
.
 CD spectra were analysed by the method of
CONTIN, (Provencher and Glockner 1981), using the set of
spectra of 48 proteins, SD48, that includes Wve denatured
proteins, (Sreerama and Woody 2000). Data were
smoothed with standard polynomial procedures; truncation
of data to 205 nm did not signiWcantly aVect the numerical
analysis results. In all cases the curve Wtting was within the
experimental noise level of the accumulated spectrum. The
numerical results for composition in terms of -helix,
-sheet, turns and aperiodic (coil) structure were fully con-
sistent with those from analysis by alternative analytical
methods. Unfolding studies were performed with heating
rate 1°/min, and cooling rate (for PrP94–233) 2°/min.
Digestion of PrP by cathepsin S and other proteolytic 
enzymes
The PrP94–233 (20–60 M) was treated with cathepsins S L
or D at 30°C at diVerent weight ratios of prion protein to
enzyme in aqueous buVer at pH 5.5–7.5, containing
0.2 mM DTT and 0.2 mM EDTA. The digestion was car-
ried out in 100 l volume in 96-well plates (SaWre 2,
TECAN) in the presence of 100 M ThT, (Breydo et al.
2005). The plate was sealed with ImmunoWare tape. The
kinetics were monitored by bottom reading of Xuorescence
intensity every 10–15 min using monochromator settings of
444 nm excitation and 485 nm emission and 5 nm band-
pass, which were shown to ensure Xuorescence was moni-
tored with full exclusion of possible light scattering
artefacts. Digestion of PrP94–233 by calpain-1 was per-
formed in aqueous buVer, pH 5.5 containing 1 mM Ca2+
and 0.2 mM DTT. Stock solutions were diluted as indi-
cated. All proteases were from Merck.
Mass spectrometric analysis
ESI-MS (electrospray ionization mass spectrometry) was
used to analyze the soluble products of PrP after 10 min
digestion of PrP (160 M) with cathepsin S (0.1 M) at
room temperature in 50 mM sodium acetate (pH5.5).
N-terminal protein sequence analysis and Western blot
PrP94–233 (100–160 M) was digested by cathepsin S (0.06–
0.1 M) under standard conditions in Eppendorf tubes. The
proteolytic products were analyzed during the time course
over a period of 24 h. For N-terminal sequencing, aliquots
of the digestion mixture were heated at 95°C for 15 min
and analyzed by SDS-PAGE (4–12% NuPage Mes system :
Invitrogen) under non-reducing conditions, and blotted
onto Immobilon PSQ PVDF membrane (Millipore). N-ter-
minal sequencing was performed by the PNAC Facility,
(University of Cambridge). For Western blot experiments,
protein bands were electro-blotted onto the membrane,
incubated with anti-PrP mAb AH6 (1 g/ml) (IAH, Comp-
ton, UK) followed by incubation with donkey anti-mouse
IRQye800 conjugate (1:5,000 dilution, Rockland) and Xuo-
rescent detection on Odyssey® Imaging System (Li-Cor
Biotechnology).
Proteinase K digestion
The pelleted material after digestion of PrP94–233 (0.5 mg/
ml) by cathepsin S was treated with Proteinase K (Qiagen)
in 50 mM Tris (pH 7.5) at 37°C, using diVerent weight
ratios of PrP to PK. Aliquots were removed over a period of
48 h and digestion was stopped by quenching with 2 mM
PMSF plus 4 £ SDS sample buVer, with SDS-PAGE anal-
ysis as above.
Results
Plate reader Xuorescence assay of PrP aggregation
The time course of digestion of PrP94–233 by cathepsin S,
(studied in a 96-well plate format (Breydo et al. 2005),
showed a progressive increase in ThT Xuorescence with a
characteristic lag phase and eventual attainment of a pla-
teau, correlating with production of aggregated material.
Figure 1a–d shows that increased concentrations of either
cathepsin S or PrP diminishes the lag phase and increases
the plateau value. Similar behaviour is seen from pH 5.5
to 7.5. This corresponds to the pH range encountered in
normal plasma conditions as well as the internal pH of
vesicles. At the higher pH values, and with increased
concentration of cathepsin S, the plateau eventually
decreases, correlating with the digestion of the aggregated
material.
Analysis of proteolytic fragments
The time-dependent evolution of the products of the diges-
tion of PrP94–233 by cathepsin S at ratio 1:1,500, was ana-
lysed on non-reducing SDS PAGE gels for the total
digestion mixture, Fig. 2a and for the precipitate and super-
natant separated by centrifugation, (Fig. 2b, c). The precipi-
tate and supernatant account for all the bands observed in
the total digest. No precipitate was observed at time zero,
but became evident at approximately 3 h, increasing there-
after, Fig. 2b. Soluble PrP fragments are identiWed from123
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were blotted for N-terminal sequencing of the numbered
bands, and the relative amounts of the diVerent proteolytic
fragments are presented in Table 1. N-terminal analysis
shows that the precipitate (band 1–2, Fig. 2b) is composed
of fragments with N-terminal sequences 135SAMS and
144FGND in similar quantities. Fragments in the super-
natant (bands 4–7) correspond to 135SAMS and shorter
sequences, and the fastest band which contains the N-termi-
nal His tag sequence of the recombinant PrP94–233.
An initial mass spectrometry analysis of the digestion
mixture identiWed three major soluble fragments PrP135–233,
PrP117–233, and PrP114–233, (data not shown). Also, on reduc-
ing gels, all bands (except band 3, which was absent)
behaved identically. These two results indicate that no
proteolytic cleavage of PrP94–233 has occurred between
Cys182 and the C-terminus, Ala233, (since this would have
led to a band of lower mass on the reducing gel) and aggre-
gation does not involve intermolecular disulphide exchange
(since pronounced diVerences would have been observed
with the non-reducing gel). The soluble band 3 also con-
tains the His tag, and is apparently a disulphide linked PrP
species, attributable to the presence of 0.2 mM DTT
required to maintain cathepsin activity. It is also seen as a
minor species in the absence of cathepsin S, (control,
Fig. 2b). At higher ratios of cathepsin S, the 144FGND
fragment constitutes a larger proportion of the insoluble
precipitate, approaching equivalence with 135SAMS. Thus
the presence of 144FGND in the digest correlates with the
appearance of aggregation.
Cleavage patterns of PrP with other proteases
N-terminal sequence analysis of these bands was used to
identify the cleavage patterns of PrP with several cathep-
sins and calpain-1, which are summarized in Fig. 3. Of
these enzymes, cathepsin B and calpain-1 yield soluble
fragments whereas cathepsins S and L are most eVective
in producing ThT-positive aggregates. Cathepsin S shows
major cleavage sites at 135SAMS and 144FGND, associ-
ated with aggregation. Cathepsin L has three main cleav-
age sites and produces a precipitate with 135SAMS,
144FGND and 146NDYE in similar amounts, together
with signiWcant amounts of shorter species 160YPNQV
Fig. 1 The ThT-binding assay 
kinetics digestion of 20 M 
PrP94–233 by cathepsin S at 30°C, 
at pH values 5.5–7.5 (a–d), and 
at diVerent ratios of PrP94–233 to 
cathepsin S,(open circle) 
1500:1, (open triangle) 200:1, 
(inverted Wlled triangle) 50:1. 
Control: (Wlled square) undi-
gested rPrP94–233
Fig. 2 PAGE analysis of the time course of digestion of 60 M PrP94–233
by 0.04 M cathepsin S (1,500:1) at 30°C, pH5.5. a Total digestion
mixture; b precipitate; c supernatant. Control: PrP incubated alone
(3 h) in digestion buVer containing 0.2 mM DTT. The numbered bands
were subjected to N-terminal sequence analysis123
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120AAGA and 135SAMS, but does not lead to aggregate
formation on the same time scale as cathepsin S. Hence
cleavage beyond 135SAMS appears to increase the yield
of aggregates.
Properties of the aggregated material
A major characteristic of PrPSc, the disease-associated,
aggregated form of PrP, is its increased resistance of the
protein to digestion by the bacterial proteinase K (PK).
Compared with amyloid Wbrils prepared in vitro (Baskakov
et al. 2002), the resistance of the pelleted material from the
cathepsin S digestion was signiWcantly reduced (data not
shsown). Optical and electron microscopy of the products
identiWed in the ThT assay showed mainly the presence of
associations of approximately spherical aggregates, rather
than amyloid Wbrils (see Supplementary Material, Figure
S1).
Structural changes of PrP during cathepsin S proteolysis
Monitoring the time course of the digestion process contin-
uously by far UV circular dichroism shows that the confor-
mational consequences are dependent on the protein
concentration. Figure 4a, with (PrP) = 9 M, shows the
progressive and extensive loss of the typical -helical
content of PrP94–233, ( = 38%,  = 14%, turn = 19%,
coil = 29%) with conversion to a largely random coil form
Table 1 Approximate relative amounts of diVerent fragments produced by digestion of PrP94–233 by cathepsin S, determined by N-terminal
sequence analysis
Relative amounts of material analysed in bands 1–2 (precipitate, from Fig. 2b) and for bands 3–7 (supernatant Fig. 2c), the total amount (pmoles),
and the percentage of a given fragment. Fragments are denoted by the initial sequence of three residues. The GHH fragment represents a sequence
with the intact N-terminal tag, apparently a dimeric PrP species in the minor band 3 of the supernatant. The control (Fig. 2) shows a minor con-
tamination of this species in the absence of digestion, probably due to the low concentration of DTT present in the buVer in order to maintain the
protease activity
Sequence GHH HVA GAA GLG GYM 135SAM DYE 144FGN




SUP:4 50 56 40 4
SUP:5 28 21 21 29 7 21
SUP:6 177 48 46 4 3
SUP:7 106 14 33 19 28 5
Fig. 4 Time course of the de-
crease in far UV circular dichro-
ism showing the conformational 
change of PrP94–233 digested by 
cathepsin S (200:1 w/w) in Mes 
50 mM pH 6.5, at 30°C; a 9 M 
PrP and b 60 M PrP; c mrw at 
215 nm as function of time for 
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Fig. 3 Summary of N-terminal sequencing data for digestion of PrP94–233
by diVerent cathepsins. Dotted arrows indicate the N-terminus of
cleavage products that do not generate the precipitate; solid arrows
indicate products which form precipitate. Residues 135 and 144 are
denoted single asterisk and double asterisks123
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with (PrP) = 60 M, there is a progressive conversion of
the spectrum of the -helical form to one with a single neg-
ative trough at 215 nm, typical of -structured species,
Fig. 4b. Analysis shows the Wnal conformation ( = 9%,
 = 33%, turn = 24%, coil = 34%), indicating a substantial
loss of -helix and a predominantly  !  conformational
transition. During the digestion period, under both condi-
tions, there was no evidence of CD signal distortion above
195 nm from light scattering, and no turbidity was detect-
able by visual inspection. The spectrometer dynode voltage
remained constant at 364.3 § 1.1 for A, and 374.2 § 1.2
for B, indicating the constancy of the optical transmission
of the samples. This demonstrates that in both cases, the
initial digestion product did not precipitate under the condi-
tions of the CD experiments. The concentration dependence
of this  !  transition indicates that molecular association
occurs at the higher concentration, with formation of a sol-
uble -structured intermediate that precedes the aggrega-
tion process. The time course of the CD changes are similar
in both cases (Fig. 4c) with the presence of a lag phase indi-
cating that the conformational eVects are dependent on the
initial proteolysis, and that the oligomeric molecular associ-
ation at the higher concentration is relatively rapid. Control
experiments of PrP94–233 digested with calpain-1 show a
slower decrease of -helix and gain of both  and
(turn + coil) conformational components (data not shown).
However, in contrast to the cathepsin S experiments, no
aggregation was observable in digestion with calpain-1 in
the plate assay even after several days incubation.
Stability studies
In order to further characterize the conformational diVer-
ences between Prp94–233 and its N-terminal truncations, the
sequences PrP138–233, PrP144–233 and PrP156–233 were
expressed and puriWed, and their thermal stability com-
pared to that of PrP94–233 was examined by far UV circular
dichroism. All showed decreased solubility and a ten-
dency to slow aggregation in Tris pH 7.5, buVer, but, at
low concentration, all species showed a single thermal
unfolding transition, Fig. 5a. This was only partially
reversible on cooling, (»50% for PrP94–233 and 20% for
the shorter fragments), with visible turbidity. All frag-
ments were signiWcantly more soluble in 1 M GuHCl,
without signiWcant loss of normal -helical secondary
structure. EVectively fully (>95%) reversible thermal
unfolding was observed PrP94–233 in 1 M GuHCl with a
Tm = 58.2°C. Reversibility of 90, 85 and 75, and Tm values
of 48.3, 47.1 and 45.6°C were observed for PrP138–233,
PrP144–233 and PrP156–233, respectively, Fig. 5b. These
results indicate a signiWcant discontinuous loss of thermo-
dynamic stability of these species lacking N-terminal resi-
dues preceding -helix 1. This sequence includes the short
1 seqeunce (MLG,132–134) that engages in antiparallel,
intramolecular interaction with 2, (QVY,163–165). The
near UV CD of PrP94–233 shows that the conformation of
aromatic side-chains is signiWcantly aVected by the pres-
ence of 1 M GuHCl, Fig. 5c. (Ov)PrP94–233 contains a
single Trp residue (W102) in a region that appears
unstructured in both NMR and crystallographic studies
(Haire et al. 2004), plus 12 Tyr residues, which are located
in two clusters within the globular domain linked by helix
3, and which include three Tyr–Tyr dipeptide repeats. The
diVerence spectrum (Fig. 5c) has the form of a CD ‘cou-
plet’, with positive and negative lobes, consistent with
electronic interactions amongst the Tyr residues being at
least partially disrupted in 1 M GuHCl. The perturbation
of tertiary structure with unchanged secondary structure is
typical of a molten globule conformation. This state has
recently been proposed for the -rich oligomeric form of
PrP (O’Sullivan et al. 2007), and for an intermediate con-
formational precursor (Gerber et al. 2007), both observed
under mildly denaturing and low pH conditions in vitro.
Fig. 5 Stability studies: a and b thermal unfolding of PrP94–233,
PrP138–233, PrP144–233 and PrP156–233 in a 50 mM Tris buVer, pH 7.5 and
b the same containing 1 M GuHCl: the dashed line is the cooling curve
for PrP94–233. In all cases, the unfolding transition represents a decrease
of 27–40% of the signal at 215 nm. c Near UVCD of PrP94–233 in Tris,




































































Eur Biophys J (2009) 38:209–218 215Interestingly, the use of 1 M GuHCl has been the basis of
several in vitro conformational conversion assays for PrP
(Caughey et al. 1999), and partially denaturing conditions
involving low pH, GuHCl, urea and salt, plus mechanical
agitation) are well established means of generating Prp
amyloid Wbrils (Morillas et al. 2001; Baskakov et al.
2002). We conclude that loss of the -1 sequence by pro-
teolysis under more normal neutral solution conditions
causes a signiWcant conformational perturbation of the
globular domain of Prp, leading to – transformation,
accompanied by oligomerisation of the  state.
Discussion
Previous extensive studies have illustrated the ability of
several unstructured peptide fragments of PrP to adopt
-structure and to form insoluble Wbrils, often at low pH,
mimicking the conditions of the endosomal compartment,
(Tagliavini et al. 2001; Jamin et al. 2002). In fact the short
sequence PrP172–178 is closely related to the Sup35 hepta-
peptide that has been shown to form a -structured polar
zipper, (Nelson et al. 2005; Sawaya et al. 2007). In addi-
tion, the mixtures of digestion products of PrP with com-
mon non-physiological proteases have been shown by
dynamic light scattering to produce large aggregates in a
time-dependent process, (Georgieva et al. 2004). No corre-
lation has been established to date between such short frag-
ments and potential pathogenicity in prion diseases.
However these results indicate a number of possible candi-
dates for initiation of -structure formation in PrP, or alter-
natively that, once initiated, -structure can become the
predominant conformation for a large fraction of the
sequence, possibly limited by the persistence of the intra-
molecular disulphide bond.
We show by N-terminal sequence analysis that the
region of PrP between S135 and N146 is a major target for
selective cleavage cathepsins S and L. The proteolysis by
calpain-1 produces mainly 135SAMS, but without aggre-
gation on the same time scale. We deduce that the shorter
fragment, 144FGND, apparently formed from, or in paral-
lel with, 135SAMS by cathepsin S, is an eYcient promoter
of this aggregation step. Monitoring of the cathepsin S-
dependent assembly process by ThT Xuorescence and of
protein conformation by far-UV CD indicates the initial
formation of a soluble form of proteolysed PrP species
that loses much of the -helical structure (initially»38%),
and adopts a conformation with a signiWcantly increased
proportion (»33%)of -structure. The structural mecha-
nism whereby proteolysis leads to this conformational
conversion involves cleavage of the globular domain
PrP94–233 in the region of residue S135, leading to more
extensive proteolysis by cathepsin S. In the intact globular
domain, (with helices 2 and 3 linked by the disulphide
bridge), the helices 1–3 form the stable core of the globu-
lar domain with the lowest degree of thermal motion
(Haire et al. 2004), 1 and 2 strands form the short -
sheet, and residues 134 to 137 are relatively mobile. The
thermal stability studies show that sequences lacking the
1 strand are signiWcantly less stable than PrP94–233, and
are more prone to aggregation. In the absence of 1, the
detachment of the relatively mobile extended sequence
(135–144) prior to -helix H1 could give access to the
cathepsin-speciWc site prior at 144F, and the proteolytic
release of residues up to 144F exposes several hydropho-
bic residues. The formation of the 144FGND fragment by
cathepsin S promotes the formation of the strongly ThT-
positive aggregated form containing both 135SAMS and
144FGND. The far UVCD data indicate that the species
initially formed with enhanced intermolecular -structure
are soluble and hence are conformational precursors of the
aggregated state.
The destabilisation of the core of the globular domain by
proteolysis in the region between the secondary structural
elements 1 and -helix H1 is consistent with previous con-
formational studies on two N-terminal deletion/truncation
mutants of mouse PrP globular domain 121–231, mutant
H1 with H1 replaced by a short -turn, and mutant H2H3,
MoPrP170–231, that lacks 1, but contains the two last heli-
ces, (Eberl and Glockshuber 2002). Both mutants are
signiWcantly destabilized relative to the globular domain
(MoPrP121–231). Both retain some -helical structure, but,
consistent with the present Wndings, mutant H2H3 is the
less stable. The extensive conformational conversion on
proteolysis of PrP by cathepsin S observed by far UVCD
must involve a substantial fraction of the residues of the
PrP globular domain, and this conformational conversion is
further driven by intermolecular association to produce the
soluble oligomeric intermediate.
The key role of the 1 sequence as shown by the proteol-
ysis results suggets a consistent molecular mechanism for
the generation of extensive -sheet structure of PrP under
diVerent conditions. Denaturants and detergenets at concen-
trations less than those required to cause equilibrium
unfolding of the globular domain could also aVect the sta-
bility of the 1–2 interaction. Low pH could act similarly
as shown by molecular dynamic simulation (Alonso et al.
2001). The sequence immediately following 1 shows high
thermal factors in the crystal structure and mobility in
NMR properties (Haire et al. 2004), indicating only weak
interaction with the globular domain. Thus in these cases
the disruption of the intramolecular 1–2 sheet by partial
denaturation, as with the removal of the 1 sequence by
proteolysis, could act as a trigger that initiates the increase
of -structure within the domain, leading to self-association
and aggregation of the -oligomer.123
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The early sites for proteolysis of PrP94–233 by these cathep-
sins that result in aggregation occur selectively in the N-ter-
minal region of the globular domain, implying that, in vivo,
similarly proteolysed PrPc would retain its GPI anchor and
thus would remain attached to the plasma membrane. This
suggests the possibility that such a membrane bound pro-
teolytically N-truncated PrP could concentrate locally and
self-associate to form -rich intermediates of PrP under
physiological conditions that could act as nuclei for the
longer-term formation of higher oligomers. In addition, as
reported for the toxicity of oligomers of a number of amy-
loidogenic sequences, they could themselves act as potent
pathogenic lytic agents, (Kayed et al. 2004; Walsh and Sel-
koe 2007). The CD analysis shows that a key factor in the
 !  conformational conversion of PrP is the local con-
centration of the destabilised proteolytic fragment. When
the fragment is expressed in a Prpo/o mouse, it would pre-
sumably be at relatively high local concentration at the
plasma membrane, and could be toxic per se, or rendered so
by very limited proteolysis and aggregation. In the presence
of co-expressed wt-Prp, known to abrogate the rapid neona-
tal pathogenesis, the local concentration of the fragment
would be reduced, and conversion or toxicity would be sig-
niWcantly retarded.
Current knowledge (Silveira et al. 2005; Tatzelt and
Schatzl 2007) suggests that prion diseases may reXect a
multiplicity of distinct but not necessarily exclusive mecha-
nisms. Theserelect phenomena observed on widely diVerent
time-scales. On the one hand, the transmissibility of an
‘infectious’ form of PrP, is characterized by the progressive
but slow appearance of a proteinase K-resistant aggregated
form (PrPSc) containing enhanced -structure possibly gen-
erated in an endosomal low pH environment. Alternatively
the involvement of various mutated, truncated and deleted
PrP variants can lead to pathogenic phenotypes, that, in
view of their potency, act too rapidly to allow accumulation
of the PrPSc species. The striking Wnding of our work is that
cathepsin proteases, normal physiological enzymes that are
also associated with pathogenic conditions, readily generate
speciWc fragments of PrP94–233 with a clear and striking
sequence similarity to deletion and truncation mutants of
PrP, modiWed in the region of sequence 1, that are highly
toxic when expressed transgenically, (Baumann et al. 2007;
Li et al. 2007). In addition, the eYcient formation of -
structured PrP oligomers by proteolysis implies a potential
role in the early stages of certain pathogenic conditions.
However the existence of numerous disease-related point
mutations and associated variants throughout the PrP
sequence (Prusiner 1998) indicates that other regions of PrP
exert important inXuences throughout the development of
the pathogenic responses. It could be highly informative to
assess the relative contributions of these factors using
experimentally generated PrP variants with mutations to
key residues within the protease sensitive regions to pre-
vent proteolysis.
Extracellular proteases have been implicated in both
physiological and pathological states in the central ner-
vous system. Some play a crucial role in neuronal migra-
tion, neurite outgrowth and synaptic plasticity. Others are
required for neuronal death and tumour growth and inva-
sion. Various insults can disrupt the Wne control of prote-
olysis and cause pathological changes (Zhang et al. 2005).
Cathepsin S is able to work outside the lysosome and in a
wide range of pH. It is especially expressed in cells of a
mononuclear lineage including microglia. Gene knock-out
results have revealed that cathepsin S and other cathepsins
carry out their speciWc functions by limited proteolysis of
proteins (Turk et al. 2000). There is increasing evidence
that disturbance of the normal balance of cathepsins con-
tribute to neurodegeneration (Nakanishi 2003). One of the
recently discovered functions of cathepsin S in the brain is
its role in the migration and activation of microglia to pro-
tect motor neurons against injury, (Hao et al. 2007). It was
shown that cathepsin S releases a soluble chemokine FLK
from the cellular surface of some neurons that is able to
stimulate microglia to secrete speciWc soluble mediators
of neuronal activity (Clark et al. 2007). New data demon-
strate that cathepsin S is also involved in some important
pathological events including Alzheimer and prion dis-
eases. The activation of cathepsins was found to be an
upstream event in the experimental scrapie model (Xiang
et al. 2004). The ME7 model of murine prion disease
shows an atypical inXammatory response characterized by
morphologically activated microglia and an anti-inXam-
matory cytokine proWle with a marked expression of TGF-
1 (Baker et al. 1999). TGF-1 plays a critical role in the
down-regulation of microglial responses minimizing brain
inXammation and damage caused by reactive oxygen
species and extracellular proteases. Up-regulation of
cathepsin S and other cathepsins in activated glia may
signiWcantly contribute to neurodegeneration. Cathepsin S
was found in exosomes released by activated microglia
(Potolicchio et al. 2005). This observation may provide a
mechanism of a fast and speciWc delivery of cathepsin S
and other reagents to neurons that could be mediated via
exosomes released by activated microglia. The physiolog-
ical advantage of exosome transport in the brain can be
justiWed because this organ, in which cell motility is
greatly restricted, needs an integral reliable communica-
tion between glia and neurons to support neuronal metab-
olism and to act quickly in response to brain injury,
proinXammatory events and invasion of pathogens. How-
ever, exosomes have also recently been reported to be car-
riers of proteins associated with several amyloid diseases123
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transported PrP could also serve to amplify incipient neu-
ropathogenic conditions. It would clearly be of interest to
know if there is link between proteolysis, conversion and
aggregation process, and the generation and secretion of
exosomes. Elevated levels of PrPc expression in the pres-
ence of reactive oxygen and nitrogen species, rapid recy-
cling, speciWc proteolysis and signiWcant pH dependent
conformational changes suggest that PrPc is able to sense
various external stimuli and to transmit conformational
changes into intra- and intercellular signals. The loss of
the N-terminus may disrupt normal PrP functions and
cause the anomalous signalling of truncated protein
(Shmerling et al. 1998). PrP is also very sensitive to other
abnormal interactions such as the cross-linking anti-PrP
monoclonal antibodies D13 and P that were shown to be
highly toxic in in vivo experiments (Solforosi et al. 2004).
These data show that there are multiple ways in which PrP
may lose its function and might convert into a toxic form,
including the loss of the N-terminus as a result of speciWc
proteolytic cleavage.
The in vitro proteolysis studies reported here represent a
substantial simpliWcation of the complex physiological
system, reduced to the actions and interactions of a small
number of puriWed components. In this case we have
concentrated on the action on PrP of cathepsin S, in view of
its speciWc elevation in conditions of scrapie pathogenesis,
though the Wndings would apply to any physiological prote-
ase of the requisite speciWcity. Examination of the potential
toxicity of the individual fragments identiWed in this work
remains to be performed. While experiments on PrP con-
version in vitro and in vivo generally relate to very diVerent
time scales, the observations of severe and relatively rapid
pathogenicity by the transgenic expression of deletion and
truncation mutants of PrP correlate with sequences that also
show slow aggregation appear to bring the two experimen-
tal time domains into closer proximity. The ability of coex-
pressed wt-PrPc to suppress the pathogenic eVects of the
mutant proteins might suggest normal cellular disposal
mechanisms can provide only limited protection against a
low threshold of toxic products. However, these mecha-
nisms may be insuYcient to counteract the eVects of a
localized overload of aggregated material and enhanced
protease activity under disease conditions. Understanding
of this important protective mechanism would add signiW-
cantly to the identiWcation of agents highly relevant to the
development of therapeutic interventions against prion
diseases.
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